AstraZeneca PLC (AZN) Deep Dive Video

Summary

AstraZeneca is trying to outrun near-term patent cliffs with a catalyst-heavy pipeline—leveraging oncology/ADC leadership, rare-disease durability, and a new obesity push to credibly chase $80B revenue by 2030.

View AZN stock page · Read the AZN research report

Loading the video player…